Cargando…
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results
INTRODUCTION: We report an exploratory analysis of the efficacy and safety of certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) (NCT03051217). METHODS: Patients ≥ 20 years with GPP or EP were randomized 1:1 to open-label CZP 400 ...
Autores principales: | Okubo, Yukari, Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209588/ https://www.ncbi.nlm.nih.gov/pubmed/35622315 http://dx.doi.org/10.1007/s13555-022-00741-x |
Ejemplares similares
-
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021) -
Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
por: Umezawa, Yoshinori, et al.
Publicado: (2021) -
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
por: Imafuku, Shinichi, et al.
Publicado: (2021) -
Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021) -
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)
por: Saeki, Hidehisa, et al.
Publicado: (2016)